Therapy News and Research

RSS

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

9 Jul 2010

AHF: 15 Zambian health care professionals to train HIV Medics

Graduation ceremonies will be held Saturday, July 10th in Lukasa for 15 Zambian health care professionals from several districts throughout the country who have completed an educational training program administered by AIDS Healthcare Foundation. This will enable the graduates to train classes of HIV Medics to work in the country's growing fight against HIV/AIDS.

9 Jul 2010

Oklahoma City ProCure Proton Therapy Center celebrates first-year anniversary

Past and present patients, families, friends, staff and physicians of ProCure Proton Therapy Center in Oklahoma City commemorated a year of achievements at a celebratory luncheon Thursday at the center in northwest Oklahoma City.

9 Jul 2010

New method enhances delivery of DNA payloads into cells

Chang Lu and his chemical engineering research group at Virginia Tech have discovered how to "greatly enhance" the delivery of DNA payloads into cells. The description of their work will be featured on the cover of Lab on a Chip (issue 16), the premier journal for researchers in microfluidics.

9 Jul 2010

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Using a small molecule decoy, investigators funded by the Samuel Waxman Cancer Research Foundation have managed to block protein interactions and induce epigenetic reprogramming in human and mouse breast cancer cells, essentially changing the gene expression of breast cancer cells to behave in a more normal manner.

9 Jul 2010

Skandion Clinic selects IBA for installation of particle therapy facility

IBA (Ion Beam Applications S.A.) announced that Skandion Clinic, the clinical centre for proton therapy in Sweden, has selected IBA for the installation of a particle therapy facility. This new center will be managed by a consortium of seven Swedish counties, representing eight university hospitals.

9 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Study identifies a region in human genome that is linked to FSGS

An in-depth study of a family with multiple generations affected by kidney disease has identified a previously unknown location for a gene abnormality causing focal segmental glomerulosclerosis, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

9 Jul 2010

Early knowledge of HCC response to TACE determines treatment success: Research article

Early knowledge of hepatocellular carcinoma response to transcatheter arterial chemoembolization is crucial for determining treatment success, timing of repeat treatment, and patient prognosis. Currently, magnetic resonance imaging is used 1-3 mo after treatment to evaluate anatomical tumor response, based upon changes in tumor size and contrast-agent enhancement. Alternatively, diffusion-weighted imaging can be used as a functional imaging technique to depict thermally induced motion of water molecules.

9 Jul 2010

Biologists discover new way to limit formation of teratomas

One of the characteristics of embryonic stem cells is their ability to form unusual tumors called teratomas. These tumors, which contain a mixture of cells from a variety of tissues and organs of the body, are typically benign. But they present a major obstacle to the development of human embryonic stem cell therapies that seek to treat a variety of human ailments such as Parkinson's, diabetes, genetic blood disorders and spinal cord injuries.

9 Jul 2010

Student-led team awarded top honor in 2010 CIMIT Prize in Primary Healthcare competition

Imagine finding out before you leave the pediatrician's office if your child has strep throat, or even something more serious requiring a different treatment. A novel application for applying DNA "nanobarcodes" in a clinical assay could help primary-care physicians quickly and more accurately determine what's causing a patient's acute pharyngitis from an easy throat swab.

9 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

A new study has found that endoscopic ultrasound (EUS) is associated with improved outcomes in patients with localized pancreatic cancer, possibly due to the detection of earlier cancers and improved stage-appropriate management, including more selective performance of curative intent surgery. This is the first study to analyze a large population-based cancer registry and demonstrate that EUS evaluation is associated with improved pancreatic cancer survival.

9 Jul 2010

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have discovered that the two fragrances Vertacetal-coeur (VC) and the chemical variation (PI24513) have the same molecular mechanism of action and are as strong as the commonly prescribed barbiturates or propofol.

9 Jul 2010

Roxane announces FDA approval for Anastrozole Tablets ANDA

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Anastrozole Tablets, 1mg by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide.

9 Jul 2010

Medicare agency releases data on hospital performance

MedPage Today: "The public can now review data on the quality of outpatient care provided by individual hospitals at the Centers for Medicare and Medicaid Services' Hospital Compare website. The site previously contained only data on inpatient care quality. All the data are derived from records of Medicare patients treated at more than 3,600 hospitals nationwide."

9 Jul 2010

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

BioCurex Inc. today announced its first set of results supporting the use of the BioCurex RECAF blood test to monitor cancer therapy. The test included samples from 27 human patients with early stages of breast cancer that were tested before and after surgery. As a control, 15 samples from healthy individuals were also tested.

9 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

Therapy News and Research

Semuloparin reduces incidence of VTE in orthopedic surgery patients, study finds

AHF: 15 Zambian health care professionals to train HIV Medics

Oklahoma City ProCure Proton Therapy Center celebrates first-year anniversary

New method enhances delivery of DNA payloads into cells

Promising study may lead to potential new therapeutics for women facing triple-negative breast cancer

Skandion Clinic selects IBA for installation of particle therapy facility

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Study identifies a region in human genome that is linked to FSGS

Early knowledge of HCC response to TACE determines treatment success: Research article

Biologists discover new way to limit formation of teratomas

Student-led team awarded top honor in 2010 CIMIT Prize in Primary Healthcare competition

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

Patients enrolled in CLARITY-AF study

Study finds EUS associated with improved outcomes in patients with localized pancreatic cancer

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Roxane announces FDA approval for Anastrozole Tablets ANDA

Medicare agency releases data on hospital performance

BioCurex reports first set of results supporting RECAF blood test for monitoring cancer therapy

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Fibrocell Science completes enrollment in azficel-T histology study

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News